Gemcitabine and carboplatin combination as first-line treatment in elderly patients and those unfit for cisplatin-based chemotherapy with advanced bladder carcinoma: Phase II study of the Hellenic Co-operative Oncology Group

Urology

Volumn 64, Issue 3, 2004, Pages 479-484

  Linardou, Helena ^a   Aravantinos, Gerassimos ^b   Efstathiou, Eleni ^c   Kalofonos, Charalambos ^d   Anagnostopoulos, Athanasios ^c   Deliveliotis, Charalambos ^c   Bafaloukos, Dimitrios ^a   Athanasios Dimopoulos, Meletios ^c   Bamias, Aristotelis ^c,e  

^a METROPOLITAN HOSPITAL   (Greece)

^b AGII ANARGIRI CANCER HOSPITAL   (Greece)

^c UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^d UNIVERSITY OF PATRAS   (Greece)

^e UNIVERSITY OF IOANNINA   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; CISPLATIN; GEMCITABINE;

ADULT; AGED; ALOPECIA; ANEMIA; ARTICLE; BLADDER CARCINOMA; CANCER GROWTH; CLINICAL TRIAL; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DRUG EFFICACY; DRUG SAFETY; EVALUATION; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NEUTROPENIA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; THROMBOCYTOPENIA; TREATMENT OUTCOME;

AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; AREA UNDER CURVE; CARBOPLATIN; CARCINOMA; CARCINOMA, TRANSITIONAL CELL; CISPLATIN; DEOXYCYTIDINE; FEMALE; HEMATOLOGIC DISEASES; HUMANS; KIDNEY FUNCTION TESTS; LIFE TABLES; MALE; NEOPLASM METASTASIS; SURVIVAL ANALYSIS; TREATMENT OUTCOME; URINARY BLADDER NEOPLASMS;

EID: 4444369379     PISSN: 00904295     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.urology.2004.04.024     Document Type: Article

References (28)

1. Sternberg C.N., Yagoda A., Scher H.I., et al. Methotrexate, vinblastine, doxorubicin, and cisplatin for advanced transitional cell carcinoma of the urothelium. Cancer. 64:1989;2448-2458
2. Logothetis C.J., Dexeus F.H., Finn L., et al. A prospective randomised trial comparing MVAC and CISCA chemotherapy for patients with metastatic urothelial tumours. J Clin Oncol. 8:1990;1050-1055
3. Loehrer P.J., Einhorn L.H., Elson P.J., et al. A randomised comparison of cisplatin alone or in combinations with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: a co-operative group study. J Clin Oncol. 10:1992;1066-1073
4. Waxman J., Barton C. Carboplatin-based chemotherapy for bladder cancer. Cancer Treat Rev. 19:1993;21-25
5. Small E.J., Lew D., Redman B.G., et al. Southwest Oncology Group study of paclitaxel and carboplatin for advanced transitional-cell carcinoma: the importance of survival as a clinical trial end point. J Clin Oncol. 18:2000;2537-2544
6. Skarlos D.V., Aravantinos G., Linardou H., et al. Chemotherapy with methotrexate, vinblastine, epirubicin and carboplatin (Carbo-MVE) in transitional cell urothelial cancer: a Hellenic Cooperative Oncology Group study. Eur Urol. 31:1997;420-427
7. Bellmunt J., Ribas A., Eres N., et al. Carboplatin-based versus cisplatin-based chemotherapy in the treatment of surgically incurable advanced bladder carcinoma. Cancer. 80:1997;1966-1972
8. Vaughn D.J., Malkowicz S.B., Zoltick B., et al. Paclitaxel plus carboplatin in advanced carcinoma of the urothelium: an active and tolerable outpatients regimen. J Clin Oncol. 16:1998;255-260
9. Redman B.G., Smith D.C., Flaherty L., et al. Phase II trial of paclitaxel and carboplatin in the treatment of advanced urothelial carcinoma. J Clin Oncol. 16:1998;1844-1848
10. Peters GJ, Bergman AM, Ruiz van Haperen VW, et al. Interaction between cisplatin and gemcitabine in vitro and in vivo. Semin Oncol 22(4 suppl 11): 72-79, 1995
11. Moore M.J., Tannock I.F., Ernst K.S., et al. Gemcitabine: a promising new agent in the treatment of advanced urothelial cancer. J Clin Oncol. 12:1997;3441-3445
12. Vogelzang N.J., Stadler W.M. Gemcitabine and other new chemotherapeutic agents for the treatment of metastatic bladder cancer. Urology. 53:1999;243-250
13. Von der Maase H., Hansen S.W., Roberts J.T., et al. Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large randomised, multinational, multicenter, phase III study. J Clin Oncol. 17:2000;3068-3077
14. Iaffaioli R.V., Tortoriello A., Facchini G., et al. Phase I/II study of gemcitabine and carboplatin in stage IIIB-IV non-small-cell lung cancer. J Clin Oncol. 17:1999;921-926
15. Langer CJ, Gandara DR, Calvert P, et al. Gemcitabine and carboplatin in combination: an update of phase I and phase II studies in non-small-cell lung cancer. Semin Oncol 26(1 suppl 4): 12-18, 1999
16. Calvert A.H., Newell D.R., Gumbrell L.A., et al. Carboplatin dosage: prospective evaluation of a simple formula based on renal function. J Clin Oncol. 7:1989;1748-1756
17. Cockroft D.W., Gault M.H. Prediction of creatinine clearance from serum creatinine. Nephron. 16:1976;31-41
18. Miller A.B., Hoogstraten B., Staquet M., et al. Reporting results of cancer treatment. Cancer. 47:1981;207-214
19. Kaplan E., Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 53:1958;457-481
20. Bajorin D.F., Dodd P.M., Mazumdar M., et al. Long-term survival in metastatic transitional-cell carcinoma and prognostic factors predicting outcome of therapy. J Clin Oncol. 17:1999;3173-3181
21. Balducci L., Exterman M. Management of cancer in the older person: a practical approach. Oncologist. 5:2000;224-237
22. Zielinski C.C., Schnack B., Grbovic M., et al. Paclitaxel and carboplatin in patients with metastatic urothelial cancer: results of a phase II trial. Br J Cancer. 78:1998;370-374
23. Carles J., Nogue M., Domenech M., et al. Carboplatin-gemcitabine treatment of patients with transitional cell carcinoma of the bladder and impaired renal function. Oncology. 59:2000;24-27
24. Shannon C., Crombie C., Brooks A., et al. Carboplatin and gemcitabine in metastatic transitional cell carcinoma of the urothelium: effective treatment of patients with poor prognostic features. Ann Oncol. 12:2001;947-952
25. Nogue-Aliguer M., Carles J., Arrivi A., et al. Gemcitabine and carboplatin in advanced transitional cell carcinoma of the urinary tract. Cancer. 97:2003;2180-2186
26. Carteni G., Dogliotti L., Crucitta E., et al. Phase II randomised trial of gemcitabine plus cisplatin (GP) and gemcitabine plus carboplatin (GC) in patients (pts) with advanced or metastatic transitional cell carcinoma of the urothelium (TCCU) (Abstract). Proc Am Soc Clin Oncol. 22:2003;384
27. Dimopoulos M.A., Moulopoulos L.A. Role of adjuvant chemotherapy in the treatment of invasive carcinoma of the urinary bladder. J Clin Oncol. 16:1998;1601-1612
28. Bellmunt J., de Wit R., Albanell J., et al. A feasibility study of carboplatin with fixed dose of gemcitabine in "unfit" patients with advanced bladder cancer. Eur J Cancer. 37:2001;2212-2215